Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBT (2022 - 2025)

Historic EBT for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.

  • Taysha Gene Therapies' EBT fell 2962.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 1565.51%. This contributed to the annual value of -$84.6 million for FY2024, which is 1456.17% down from last year.
  • Per Taysha Gene Therapies' latest filing, its EBT stood at -$30.9 million for Q3 2025, which was down 2962.42% from -$24.9 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' EBT peaked at -$15.0 million during Q4 2023, and registered a low of -$55.1 million during Q4 2022.
  • In the last 4 years, Taysha Gene Therapies' EBT had a median value of -$23.8 million in 2024 and averaged -$26.7 million.
  • Per our database at Business Quant, Taysha Gene Therapies' EBT skyrocketed by 7269.39% in 2023 and then plummeted by 4336.02% in 2024.
  • Taysha Gene Therapies' EBT (Quarter) stood at -$55.1 million in 2022, then surged by 72.69% to -$15.0 million in 2023, then fell by 21.39% to -$18.3 million in 2024, then plummeted by 69.11% to -$30.9 million in 2025.
  • Its EBT was -$30.9 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$20.1 million in Q1 2025.